12:00 AM
 | 
Nov 04, 2002
 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch

Date Company Staff cuts Notes Cash Years cash pre-cut Cash reporting date
10/29 Abgenix (ABGX) 15% to about 386 Plans to partner its therapeutic antibodies when they are in preclinical development, rather than in the clinic, and hopes to end 2003 with three years of operating cash $464.0 3.6 9/30
10/10 Advanced Tissue (ATIS) 82% to 40 Filed for Chapter 11. Partner Smith...

Read the full 443 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >